What’s next for you jokers now that you FINALLLLLLY got approval? So quiet here. Is anyone even home? Are you also surprised you got approved? Still can’t compete with Pacira? Hello? Bueller?
What’s Next?
- Thread starter anonymous
- Start date
-
- Tags
- None
Off course it’s going to be quite as dreams of becoming overnight millionaire for many just got crushed especially for the ones living off of oncology dollars.
One suggestion to CCO JP, stop listening to MM and don’t be so loose with your words. Get the definition of blockbuster right before putting it on slides. This is not going to be a blockbuster at least not during your tenure. - Pacira Commercial Team.
Does the labels suck? That might be a reason the stock is down..
Dear Barry, you big mustache twirling dweeb, you have failed to deliver stock appreciation yet again.
Need I remind you that this is your one and only job?
Sincerely,
The BOD
Need I remind you that this is your one and only job?
Sincerely,
The BOD
Stock is down due to restricted label. If we didn’t get expanded label due to higher FDA hurdles put in place over last 2 years WHILE WE DICKED AROUND WITH 2 CRLs then I STILL BLAME OUR CMC TEAM FOR THIS!
You do not fuck with the FDA. Do it right, the way they like it, THE FIRST TIME!
Yes, we have great sales force that made sustol a blockbuster is in place already and more idiots sorry “rockstars” are coming.
Given the restrictive label, it’s just a matter of time before we get caught for off-label promotion.
This company and leadership stinks. Two CRLs and the BOD does nothing. BQ is ultimately responsible and should be shown the door.
Rough week in the broader stock market, but Thursday and Friday were good EXCEPT HRTX. S&P 500, Nasdaq down 1.5%-3% for the week and we are down close to 15%.
Jackasses.
Another underwhelming performance by BQ and the leadership team. I thought the CEO is supposed to set strategy to increase shareholder value.
This company and leadership stinks. Two CRLs and the BOD does nothing. BQ is ultimately responsible and should be shown the door.
Rough week in the broader stock market, but Thursday and Friday were good EXCEPT HRTX. S&P 500, Nasdaq down 1.5%-3% for the week and we are down close to 15%.
Jackasses.
Another underwhelming performance by BQ and the leadership team. I thought the CEO is supposed to set strategy to increase shareholder value.
Two days after FDA approval and HRTX stock prices the lowest ever! Ready to launch this SUCK DRUG??? START INTERVIEWING FOR YOUR NEXT JOB NOW!
There was so much off-label talk during yesterday’s investor call which we all know is a big no no. I think it’s all desperation.
Or maybe BQ doesn’t want employees to benefit from this and on purpose gave negative outlook by using the word “unfortunately” many times during the call. SEC should probe into this and file a lawsuit on these guys.
Or maybe BQ doesn’t want employees to benefit from this and on purpose gave negative outlook by using the word “unfortunately” many times during the call. SEC should probe into this and file a lawsuit on these guys.
Yeah, that call was pretty bad. They could barely speak, sounded like the just got baton raped by the FDA and they hadn’t come to their senses yet. And what’s with letting the doc say he’s ready to start prescribing off label...on a company call. Barry is a fucking moron.
Yeah, that call was pretty bad. They could barely speak, sounded like the just got baton raped by the FDA and they hadn’t come to their senses yet. And what’s with letting the doc say he’s ready to start prescribing off label...on a company call. Barry is a fucking moron.
Finally someone else who thinks they sounded bad on the call. Seemed like everyone on the call was stuttering and falling over themselves. Very confidence inspiring.
So after all of the build-up, this is it? Can you say done by the end of the year??? Stock still in the gutter! Not inspiring!
What a joke!
The label blows. The idea that you can sell it off label in this hospital environment is ludicrous.
It’ll be fun to watch all the leftover Pacira reps “pivot” into nerve block with the pending lawsuit against the ASA while everyone infiltrating Exparel upgrades to Zynrelef. Limited label won’t be a major problem, 60% of Exparel’s business is in Ortho and nobody likes making 120 sticks in a TKA. Hospitals were already looking for a reason to kick Exparel out before their price increases,